Latest Regulatory Approvals News

Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.

Sea Forest Limited (ASX:SEA) reported a spectacular 486% surge in SeaFeed revenue for FY26, underpinned by 131,000 cattle committed, surpassing breakeven targets, and a robust $27.8 million cash buffer. The company advances its commercial footprint domestically and internationally, with carbon credit revenue set to kick off in late 2027.

Elevra Lithium posted a $44 million profit in FY26 after merging Sayona Mining and Piedmont Lithium, overcoming temporary mining challenges and securing full funding for the North American Lithium expansion.

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Vault Minerals has secured a key regulatory waiver from the ACCC for its merger with Genesis Minerals, removing a major obstacle and keeping the deal on track for shareholder approval later this year.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Syntara Limited’s FY2026 results show a 7.9% revenue decline and a 13.6% increase in net loss amid significant clinical progress, including FDA backing for its lead drug amsulostat and a successful $8.8 million capital raise.

Clarity Pharmaceuticals reported a 67% increase in net loss to $107.2 million for FY26, driven by higher R&D spending, while advancing multiple Phase III trials and expanding manufacturing capacity ahead of commercialisation.

Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.

BlackWall Limited posted a $2.4 million statutory loss for FY2026, driven by operating setbacks and unrealised asset write-downs. The company suspends dividends after exhausting franking credits and proposes a share buy-back offering WOT securities in lieu of cash.

Heartland has cleared a major hurdle in its $620 million acquisition of TSB, with Toi Foundation trustees approving the sale. The merger aims to create a stronger regional challenger bank, pending shareholder and regulatory green lights.

Bathurst Resources delivered a consolidated EBITDA of NZD 44.7 million for FY26, reaching the top of its guidance despite a challenging start to the year for export coal prices. The company advanced key growth projects in New Zealand and Canada while maintaining a robust cash position.